U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Turn Therapeutics (TTRX) will participate in a U.S. Bancorp | BTIG virtual fireside chat on October 28, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Date: Wednesday, October 28, 2026
Time: 10:00 AM ET
The fireside chat, "Building a Program for Patient Access in Atopic Dermatitis,” will focus on the company’s strategy for developing GX-03, its lead investigational therapy, in line with its mission to increase access to effective medicines for high-need populations.
This event is open to U.S. Bancorp | BTIG institutional clients. Interested investors should contact their BTIG sales representative to attend.
About Turn Therapeutics
Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies designed to act directly at the site of disease. The Company's lead therapeutic candidate, GX-03, is being evaluated in atopic dermatitis and is also being developed for onychomycosis. Turn's research focuses on the intersection of microbial activity, local immune signaling and chronic inflammation.
For more information, visit www.turntherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261021279897/en/
Investor Relations / Media Contact
Sasha Damouni
Damouni Group, LLC
sasha@turntherapeutics.com
Source: Turn Therapeutics Inc.